Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
SCLC, Extensive Stage
Interventions
DRUG

Olvi-Vec

Olvi-Vec will be administered to patient for 3 days during C1

DRUG

platinum (cisplatin or carboplatin)

After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum (Carboplatin or Cisplatin)will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.

DRUG

Etoposide

After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.

Trial Locations (2)

Unknown

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

RECRUITING

Shanghai chest hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Chest Hospital

OTHER

collaborator

Zhejiang Provincial People's Hospital

OTHER

lead

Newsoara Biopharma Co., Ltd.

INDUSTRY